CYP3A is an enzyme subfamily in the cytochrome P450 (CYP) superfamily and includes
isoforms CYP3A4, CYP3A5, CYP3A7, and CYP3A43. CYP3A enzymes are indiscriminate …

The introduction of tacrolimus in clinical practice has improved patient survival after organ
transplant. However, despite the long use of tacrolimus in clinical practice, the best way to …

Many genetic variants in drug metabolizing enzymes and transporters have been shown to
be relevant for treating psychiatric disorders. Associations are strong enough to feature on …

Abstract Cytochrome P450 3A4 (CYP3A4) metabolizes 30–50% of clinically used drugs.
Large interperson variability in CYP3A4 activity affects response to CYP3A4 substrate drugs …

Irinotecan (SN-38) is a potent and broad-spectrum anticancer drug that targets DNA
topoisomerase I (Top1). It exerts its cytotoxic effects by binding to the Top1-DNA complex …

Objectives Tenofovir alafenamide produces lower plasma tenofovir and higher intracellular
tenofovir diphosphate (DP) concentrations than tenofovir disoproxil fumarate but it is likely a …

Immunosuppressant drugs (ISDs) are routinely used in clinical practice to maintain organ
transplant survival. However, these drugs are characterized by a restricted therapeutic …

Rivaroxaban is excreted from the body via multiple pathways involving glomerular filtration,
drug‐metabolizing enzymes and transporters. In this study, we aimed to examine the impact …

Tacrolimus, a dual substrate of CYP3A4 and CYP3A5 has a narrow therapeutic index and is
characterized by high between-subject variability in oral bioavailability. This study …

Tacrolimus trough and dose requirements vary dramatically between individuals of
European and African American ancestry. These differences are less well described in other …